Dupilumab

Generic Name: Dupilumab

Brand Names: Dupixent

Dupilumab is a biologic that blocks IL-4 and IL-13 for moderate-to-severe atopic dermatitis, asthma, and nasal polyps.

DermatologicBiologicMonoclonal Antibody

Drug Class

Interleukin-4 / Interleukin-13 Receptor Antagonist (Monoclonal Antibody)

Pregnancy

No formal FDA letter category; limited human data — use during pregnancy only if potential benefit justifies potential risk to the fetus

Available Forms

200 mg/1.14 mL prefilled syringe, 300 mg/2 mL prefilled syringe, 200 mg/1.14 mL prefilled pen, 300 mg/2 mL prefilled pen

What It's Used For

Dosage Quick Reference

These are general dosage guidelines. Your doctor will determine the appropriate dose for your specific situation.

Condition	Starting Dose	Maintenance Dose
Atopic dermatitis (adults)	600 mg subcutaneously (two 300 mg injections)	300 mg subcutaneously every 2 weeks
Asthma (moderate-to-severe, ages 12+)	400 mg subcutaneously (two 200 mg injections) or 600 mg (two 300 mg) based on comorbidities	200 mg every 2 weeks or 300 mg every 2 weeks
Chronic rhinosinusitis with nasal polyps	300 mg subcutaneously	300 mg every 2 weeks
Eosinophilic esophagitis (adults)	300 mg subcutaneously weekly	300 mg weekly for 24 weeks

Side Effects

Common Side Effects:

Injection site reactions
Conjunctivitis
Blepharitis (eyelid inflammation)
Oral herpes
Eosinophilia
Headache
Arthralgia

Serious Side Effects:

Hypersensitivity reactions including anaphylaxis
Keratitis
Helminth infection complications
Joint pain (arthralgia)
Eczema herpeticum (rare)

Drug Interactions

Live vaccines: Avoid live vaccines during dupilumab therapy; complete all age-appropriate vaccinations before initiating treatment.
CYP450 substrates (warfarin, theophylline, cyclosporine): IL-4 inhibition by dupilumab may normalize CYP450 enzyme levels that were suppressed by chronic inflammation, potentially altering drug metabolism; monitor narrow therapeutic index drugs when starting or stopping dupilumab.
Systemic corticosteroids: Dupilumab is not a corticosteroid replacement; do not abruptly discontinue corticosteroids when starting dupilumab — taper gradually under medical supervision.
Other biologics or immunosuppressants: Safety and efficacy of concurrent biologic use have not been established; avoid combining with other systemic immunomodulating therapies.

Additional Information

Dupilumab is a fully human monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling, used for the treatment of moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. This biologic targets key drivers of type 2 inflammation.

Mechanism of Action

Dupilumab is a human IgG4 monoclonal antibody that binds to the shared IL-4Rα subunit of the IL-4 and IL-13 receptor complexes. IL-4 and IL-13 are key cytokines in type 2 (Th2) inflammation, driving IgE production, eosinophil recruitment, mucus production, and tissue remodeling. By blocking IL-4Rα, dupilumab inhibits signaling from both IL-4 and IL-13, reducing type 2 inflammatory responses. In atopic dermatitis, this reduces skin inflammation and pruritus. In asthma, it reduces airway inflammation and hyperreactivity. The medication provides sustained suppression of type 2 inflammation while preserving other immune functions.

Available Formulations

Dupilumab is available as a solution for subcutaneous injection in prefilled syringes and prefilled pens containing 200 mg/1.14 mL or 300 mg/2 mL. Prefilled syringes containing 100 mg/0.67 mL are available for pediatric patients. The medication requires refrigeration but can be kept at room temperature for up to 14 days before use. Patients can self-inject after proper training.

Medical Uses

Dupilumab is FDA-approved for moderate to severe atopic dermatitis in patients 6 months and older inadequately controlled with topical therapies, moderate to severe asthma aged 6 years and older with an eosinophilic phenotype or oral corticosteroid-dependent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) in adults inadequately controlled with intranasal corticosteroids, eosinophilic esophagitis in patients 12 years and older weighing at least 40 kg, and prurigo nodularis in adults. It is the first biologic approved for atopic dermatitis.

Dosing Guidelines

For adults with atopic dermatitis or prurigo nodularis, the dose is 600 mg (two 300 mg injections) initially, followed by 300 mg every other week. For asthma (without oral corticosteroid dependence), the dose is 400 mg initially, then 200 mg every other week, or 600 mg initially then 300 mg every other week for severe disease. For CRSwNP and eosinophilic esophagitis, 300 mg every other week is used. Pediatric dosing is weight-based. Injections can be given in the thigh, abdomen (except 2 inches around navel), or upper arm.

Important Safety Information

Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. The medication should be discontinued if severe reactions occur. Conjunctivitis and keratitis are common, particularly in atopic dermatitis patients; new or worsening eye symptoms should be evaluated. Helminth infections should be treated before initiating therapy. Patients should not discontinue systemic or inhaled corticosteroids abruptly when starting dupilumab for asthma. Live vaccines should be avoided during treatment.

Drug Interactions

No formal drug interaction studies have been conducted. Dupilumab is not expected to undergo hepatic metabolism or interact with cytochrome P450 enzymes. However, the formation of CYP450 enzymes can be altered by cytokines; as dupilumab modulates IL-4 and IL-13 signaling, it could theoretically affect CYP450 substrates with narrow therapeutic indices (warfarin). Vaccines may be administered during treatment, but live vaccines should be avoided.

Special Populations

There are limited data on dupilumab use during pregnancy. Animal studies showed no evidence of harm. The medication should be used during pregnancy only if the potential benefit justifies the potential risk. It is unknown whether dupilumab is excreted in human breast milk. Safety and efficacy have been established in pediatric patients: atopic dermatitis (6 months and older), asthma (6 years and older), and eosinophilic esophagitis (12 years and older). Elderly patients do not require dose adjustment. No dose adjustment is needed for renal or hepatic impairment.

Frequently Asked Questions

Dupilumab specifically blocks the shared receptor component for both IL-4 and IL-13, two key cytokines that drive type 2 (allergic) inflammation. By targeting this specific inflammatory pathway, it addresses the underlying cause of atopic dermatitis, certain asthma phenotypes, nasal polyps, and eosinophilic esophagitis without broadly suppressing the immune system.

Unlike anti-TNF biologics, dupilumab does not significantly increase the risk of serious infections. It targets type 2 inflammation rather than broadly suppressing immunity. Clinical trials showed similar rates of serious infections between dupilumab and placebo groups.

Injection site reactions (redness, swelling, itching) are the most common side effect. Conjunctivitis and eye inflammation occur in some patients, particularly those with atopic dermatitis. These are usually mild to moderate and manageable.

Yes. After proper training from a healthcare provider, dupilumab can be self-administered at home using the prefilled syringe or pen. Injection sites (thigh, abdomen, upper arm) should be rotated, and the medication should be brought to room temperature before injection.

Many patients notice reduced itching within the first 1 to 2 weeks. Visible skin improvement typically becomes apparent within 4 to 6 weeks, with continued improvement over 16 weeks of treatment. Full benefit is usually seen by 16 weeks.

Dupilumab is often used alongside topical corticosteroids or calcineurin inhibitors for atopic dermatitis. Your doctor may gradually reduce topical treatments as your skin improves, but continuing some topical therapy is common, especially during flares.

Questions to Ask Your Doctor

Consider discussing these topics at your next appointment:

✓Is dupilumab appropriate for the severity of my condition, and are there other options I should consider first?
✓What should I do if I develop eye redness or irritation while on dupilumab?
✓Can I get vaccinations while taking dupilumab?
✓How will we determine if dupilumab is working well enough for me?
✓Will my insurance cover dupilumab, and are there patient assistance programs available?

Schedule an Appointment

Related Health Conditions

This medication is commonly used to treat or manage the following conditions:

Asthma

Asthma, a chronic lung disease, causes airway inflammation and narrowing, resulting in wheezing, coughing, and shortness of breath, triggered by allergens, irritants, infections, or stress.

Learn More

Dermatitis

Dermatitis is skin inflammation with varied causes, including irritants, allergens, genetics (eczema), yeast overgrowth, or poor circulation, resulting in itchy rashes and dryness.

Learn More

Sinusitis

Sinusitis involves sinus inflammation and blockage due to infections, allergies, or structural issues, causing facial pain, pressure, and congestion, often following colds or triggered by allergens.

Learn More

Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.